Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:
”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?
March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference
GARDEN Network – Global Hematological Rare Diseases Alliance
In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.
More than a century later, thalassemia remains primarily classified as a globin gene disorder.
That molecular basis remains central.
However, translational evidence is expanding the framework.
Dysregulated hematopoietic stem cell (HSC) biology.
Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.
These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.
This is not a semantic issue. It is a regulatory one.
A stem cell–centered model could impact:
- Mechanism-based endpoint selection
- Biomarker qualification strategies
- Trial population stratification
- Surrogate endpoint validation
- Long-term follow-up architecture
In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.
The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.
We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.
A century after its original description, reassessment may not be disruptive — it may be necessary.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies